Evidence map›Paper›PMID 33720009›Full record

ArticleeLife2021

Genetic association and causal inference converge on hyperglycaemia as a modifiable factor to improve lung function.

William R Reay, Sahar I El Shair, Michael P Geaghan, Carlos Riveros, Elizabeth G Holliday, Mark A McEvoy, Stephen Hancock, Roseanne Peel, Rodney J Scott, John R Attia and 1 more

Open access · goldAbstract read
In one paragraph

Article in eLife, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 2 pooled it
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 2 syntheses or guidelines pooled it, 18 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Observational
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

William R ReaySchool of Biomedical Sciences and Pharmacy, The University of Newcastle, Callaghan, Australia.ORCID 0000-0001-7689-2453
Sahar I El ShairSchool of Biomedical Sciences and Pharmacy, The University of Newcastle, Callaghan, Australia.
Michael P GeaghanSchool of Biomedical Sciences and Pharmacy, The University of Newcastle, Callaghan, Australia.
Carlos RiverosHunter Medical Research Institute, Newcastle, Australia.
Elizabeth G HollidayHunter Medical Research Institute, Newcastle, Australia.
Mark A McEvoyHunter Medical Research Institute, Newcastle, Australia.
Stephen HancockHunter Medical Research Institute, Newcastle, Australia.
Roseanne PeelHunter Medical Research Institute, Newcastle, Australia.
Rodney J ScottSchool of Biomedical Sciences and Pharmacy, The University of Newcastle, Callaghan, Australia.
John R AttiaHunter Medical Research Institute, Newcastle, Australia.
Murray J CairnsSchool of Biomedical Sciences and Pharmacy, The University of Newcastle, Callaghan, Australia.ORCID 0000-0003-2490-2538
Hunter Medical Research Institute · AUUniversity of Newcastle Australia · AU

Funding

National Health and Medical Research Council 1121474National Health and Medical Research Council 1147644
6 · The paper itself

Abstract

Measures of lung function are heritable, and thus, we sought to utilise genetics to propose drug-repurposing candidates that could improve respiratory outcomes. Lung function measures were found to be genetically correlated with seven druggable biochemical traits, with further evidence of a causal relationship between increased fasting glucose and diminished lung function. Moreover, we developed polygenic scores for lung function specifically within pathways with known drug targets and investigated their relationship with pulmonary phenotypes and gene expression in independent cohorts to prioritise individuals who may benefit from particular drug-repurposing opportunities. A transcriptome-wide association study (TWAS) of lung function was then performed which identified several drug-gene interactions with predicted lung function increasing modes of action. Drugs that regulate blood glucose were uncovered through both polygenic scoring and TWAS methodologies. In summary, we provided genetic justification for a number of novel drug-repurposing opportunities that could improve lung function.

Indexed as

Blood GlucoseCausalityDatabases, GeneticDrug RepositioningGenome-Wide Association StudyHumansHyperglycemiaLungLung DiseasesMultifactorial InheritancePhenotypePolymorphism, Single NucleotideRespiratory Function TestsTranscriptomeBlood Glucosecausal inferencedrug repurposinggeneticsgenomicsGWAShumanlung functionpolygenic scoringTWAS

Identifiers

PMID33720009
PMCPMC8060032
OpenAlexW3136993373

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.